文献速递白血病造血干细胞移植与细胞治疗

GIMEMA AML1310试验:风险适应和MRD指导的年轻初诊AML治疗

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
PubMed 文献 · Blood · 2019-08-08

该试验对年轻初诊急性髓系白血病(AML)患者根据细胞遗传学/遗传学和巩固后微小残留病(MRD)水平分配缓解后治疗。500例中361例(72%)达完全缓解,342例完成巩固并分配治疗。2年总生存(OS)和无病生存(DFS)分别为56%和54%。结论:自体干细胞移植(AuSCT)在预后良好和MRD阴性中危组仍有作用;MRD阳性中危组异基因移植(AlloSCT)使OS和DFS延长至与预后良好组相当。

要点

  • 预后良好组2年OS 74%、DFS 61%,可考虑自体移植。
  • MRD阴性中危组2年OS 79%、DFS 61%,自体移植仍有效。
  • MRD阳性中危组接受异基因移植后2年OS 70%、DFS 67%,与预后良好组相当。

核心结论

  • 在预后良好和MRD阴性中危组,自体干细胞移植可能仍有作用。
  • 在MRD阳性中危组,异基因移植使OS和DFS延长至与预后良好组相当。
  • 利用所有可用干细胞来源,71%的候选者接受了异基因移植。

研究设计与样本

  • 前瞻性试验纳入500例年轻初诊AML患者,根据细胞遗传学/遗传学和巩固后MRD水平分配缓解后治疗。
  • 361/500例(72%)达完全缓解,342/361例完成巩固并分配治疗:165例(48%)分配至异基因移植(122例预后不良,43例MRD阳性中危),150例(44%)分配至自体移植(115例预后良好,35例MRD阴性中危),27例(8%)中危无白血病相关免疫表型未分配。

主要发现

  • 全系列2年OS为56%,DFS为54%。
  • 预后良好组2年OS 74%、DFS 61%;预后不良组2年OS 42%、DFS 45%。
  • MRD阴性中危组2年OS 79%、DFS 61%;MRD阳性中危组2年OS 70%、DFS 67%。
  • 自体移植候选者中110/177例(62%)实际接受移植;异基因移植候选者中130/188例(71%)实际接受移植。

关键数值与推荐

  • 预后良好组计划接受自体干细胞移植,预后不良组计划接受异基因干细胞移植。
  • 中危组根据巩固后MRD水平决定接受自体或异基因移植。

临床怎么用

  • 对年轻初诊AML患者,可结合遗传学风险和巩固后MRD水平个体化选择自体或异基因移植。
  • MRD阳性中危患者可从异基因移植中获益,生存与预后良好组相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We designed a trial in which postremission therapy of young patients with de novo acute myeloid leukemia (AML) was decided combining cytogenetics/genetics and postconsolidation levels of minimal residual disease (MRD). After induction and consolidation, favorable-risk patients (FR) were to receive autologous stem cell transplant (AuSCT) and poor-risk patients (PR) allogeneic stem cell transplant (AlloSCT). Intermediate-risk patients (IR) were to receive AuSCT or AlloSCT depending on the postconsolidation levels of MRD. Three hundred sixty-one of 500 patients (72%) achieved a complete remission, 342/361 completed the consolidation phase and were treatment allocated: 165 (48%) to AlloSCT (122 PR, 43 IR MRD-positive) plus 23 rescued after salvage therapy, for a total of 188 candidates; 150 (44%) to AuSCT (115 FR, 35 IR MRD-negative) plus 27 IR patients (8%) with no leukemia-associated phenotype, for a total of 177 candidates. Overall, 110/177 (62%) and 130/188 (71%) AuSCT or AlloSCT candidates received it, respectively. Two-year overall (OS) and disease-free survival (DFS) of the whole series was 56% and 54%, respectively. Two-year OS and DFS were 74% and 61% in the FR category, 42% and 45% in the PR category, 79% and 61% in the IR MRD-negative category, and 70% and 67% in the IR MRD-positive category. In conclusion, AuSCT may still have a role in FR and IR MRD-negative categories. In the IR MRD-positive category, AlloSCT prolongs OS and DFS to equal those of the FR category. Using all the available sources of stem cells, AlloSCT was delivered to 71% of the candidates.This trial was registered at www.clinicaltrials.gov as #NCT01452646 and EudraCT as #2010-023809-36.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019. PMID: 31395600. doi:10.1182/blood.2018886960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。